Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 14/20 | 0.44 |
| ▸ | ACE | P12821 | 9/20 | 0.43 |
| ▸ | CAD | P27708 | 1/20 | 0.42 |
| ▸ | ECE1 | P42892 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6813416 | 1.00 | MME (0.44) | MMEACECADECE1KDM4E | |
| SCHEMBL6814128 | 1.00 | MME (0.44) | MMEACECADECE1KDM4E | |
| SCHEMBL4903224 | 0.98 | MME (0.46) | MMEACECADECE1KDM4E | |
| SCHEMBL18576543 | 0.98 | MME (0.46) | MMEACECADECE1KDM4E | |
| SCHEMBL15134405 | 0.98 | MME (0.46) | MMEACECADECE1KDM4E | |
| SCHEMBL20367630 | 0.98 | MME (0.46) | MMEACECADECE1KDM4E | |
| SCHEMBL630497 | 0.94 | CAD (0.43) | MMEACECAD | |
| SCHEMBL3625069 | 0.94 | CAD (0.43) | MMEACECAD | |
| SCHEMBL2344195 | 0.94 | CAD (0.43) | MMEACECAD | |
| SCHEMBL3258686 | 0.88 | FKBP5 (0.52) | MMEACEECE1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667673-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2023-06-06 | — | — | US | disclosed |
| US-20210024575-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2021-01-28 | — | — | US | disclosed |
| US-10689414-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190023737-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2019-01-24 | — | — | US | disclosed |
| US-6841682-B2 | Heterocycles useful in the treatment of benign prostatic hyperplasia | JANSEEN PHARMACEUTICA N.V. (BE) | 2005-01-11 | — | — | US | disclosed |
| EP-1273572-B1 | Thiophene substituted piperazines useful in the treatment of benign prostatic hyperplasia | ORTHO MCNEIL PHARM INC (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1273572-A1 | Thiophene substituted piperazines useful in the treatment of benign prostatic hyperplasia | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020165219-A1 | Novel heterocycles useful in the treatment of benign prostatic hyperplasia | HUTCHINGS RICHARD H (US) | 2002-11-07 | — | — | US | disclosed |
| US-6384035-B1 | TREATING A DISEASE MEDIATED BY THE .ALPHA.-1.SUB.A ADRENERGIC RECEPTOR COMPRISING ADMINISTERING A COMPOUND | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-05-07 | — | — | US | disclosed |
| EP-1025085-A1 | HETEROCYCLES USEFUL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA AND INTERMEDIATES THEREOF | Ortho-McNeil Pharmaceutical, Inc. (US) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999019299-A1 | HETEROCYCLES USEFUL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA AND INTERMEDIATES THEREOF | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-04-22 | — | — | WO | disclosed |
| US-4741818-A | COMPLEXES | LEARONAL, INC. (US) | 1988-05-03 | — | — | US | disclosed |
| EP-0225422-A1 | Alkaline baths and methods for electrodeposition of palladium and palladium alloys | LeaRonal, Inc. (US) | 1987-06-16 | — | — | EP | disclosed |
| US-4150002-A | DIMER ACIDS | SCHERING AKTIENGESELLSCHAFT (DE) | 1979-04-17 | — | — | US | disclosed |
| US-4015008-A | N,N-dichloro substituted aminocarboxylic acids as microbiocides | NATIONAL PATENT DEVELOPMENT CORPORATION (US) | 1977-03-29 | — | — | US | disclosed |
| US-3950536-A | N,N-Dichloro substituted aminocarboxylic acids as bactericides and fungicides | BARER SOL JOSEPH | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689414-B2 | Therapeutically active compounds and their methods of use | IDH1, IDH3B, IDH3A | MME 2374/4885ACE 2827/4885CAD 4620/4885 |
| US-20210024575-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | MME 2374/4885ACE 2827/4885CAD 4620/4885 |
| US-20020165219-A1 | Novel heterocycles useful in the treatment of benign prostatic hyperplasia | ADRA1A, ADRB1, ADRA1D | MME 3911/4885ACE 2839/4885CAD 2526/4885 |
| US-11667673-B2 | Therapeutically active compounds and their methods of use | IDH1, IDH3B, IDH3A | MME 2374/4885ACE 2827/4885CAD 4620/4885 |
| US-20190023737-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | MME 2374/4885ACE 2827/4885CAD 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.